Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
Our data suggest that the FDG-PET/CT ΔSUV after the second course of NAC can predict pathological response in ductal breast carcinomas, and potentially identify a subgroup of non-responding patients for whom ineffective chemotherapy should be avoided.
MLS alone is effective in managing UVFP in most patients.